BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Gastrointestinal Stromal Tumor readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Gastrointestinal Stro
 mal Tumor\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05366816-2058@assetmemo.bio
DTSTAMP:20261121T005018Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Regorafenib: Phase 2 readout est. (NCT05366816)
DESCRIPTION:Regorafenib\, phase 2\, Gastrointestinal Stromal Tumor.\nStudy:
  ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST\nEstimated primar
 y completion: 31 December 2026. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/regorafenib#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT05366816
URL:https://assetmemo.bio/drug/regorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07559864-2058@assetmemo.bio
DTSTAMP:20261121T005018Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Regorafenib: Phase 2 readout est. (NCT07559864)
DESCRIPTION:Regorafenib\, phase 2\, Gastrointestinal Stromal Tumor.\nStudy:
  Comparing Regorafenib Combined With Envafolimab to Physician's Choice in 
 Patients With Metastatic Gastrointestinal Stromal Tumors Harboring KIT Exo
 n 17 Mutations Refractory to Standard Treatment\nEstimated primary complet
 ion: 1 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/reg
 orafenib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07559864
URL:https://assetmemo.bio/drug/regorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06772233-2058@assetmemo.bio
DTSTAMP:20261121T005018Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Regorafenib: Phase 2 readout est. (NCT06772233)
DESCRIPTION:Regorafenib\, phase 2\, Gastrointestinal Stromal Tumor.\nStudy:
  A Study of Regorafenib Combined With Envafolimab for Metastatic Gastroint
 estinal Stromal Tumors With Kit Gene Exon 17 Mutation That Failed Standard
  Treatment\nEstimated primary completion: 30 July 2027. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/regorafenib#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06772233
URL:https://assetmemo.bio/drug/regorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07218926-11196@assetmemo.bio
DTSTAMP:20261121T005018Z
DTSTART;VALUE=DATE:20280530
DTEND;VALUE=DATE:20280531
SUMMARY:Velzatinib: Phase 3 readout est. (NCT07218926)
DESCRIPTION:Velzatinib\, phase 3\, Gastrointestinal Stromal Tumor.\nStudy: 
 A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With
  Gastrointestinal Stromal Tumors After Imatinib Therapy\nEstimated primary
  completion: 30 May 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/velzatinib#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07218926
URL:https://assetmemo.bio/drug/velzatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07843641-11196@assetmemo.bio
DTSTAMP:20261121T005018Z
DTSTART;VALUE=DATE:20310131
DTEND;VALUE=DATE:20310201
SUMMARY:Velzatinib: Phase 2 readout est. (NCT07843641)
DESCRIPTION:Velzatinib\, phase 2\, Gastrointestinal Stromal Tumor.\nStudy: 
 A Legacy Study in Participants With Gastrointestinal Stromal Tumors (GIST)
 \nEstimated primary completion: 31 January 2031. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/velzatinib#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07843641
URL:https://assetmemo.bio/drug/velzatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06087263-2058@assetmemo.bio
DTSTAMP:20261121T005018Z
DTSTART;VALUE=DATE:20320701
DTEND;VALUE=DATE:20320702
SUMMARY:Regorafenib: Phase 2 readout est. (NCT06087263)
DESCRIPTION:Regorafenib\, phase 2\, Gastrointestinal Stromal Tumor.\nStudy:
  Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mu
 tation Subsets (KIT Exon 17\, 18\, or 14 Mutation and SDHB Deficient GIST)
  in the Post-imatinib Second-line Setting.\nEstimated primary completion: 
 1 July 2032. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/regorafe
 nib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06087263
URL:https://assetmemo.bio/drug/regorafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07585266-11196@assetmemo.bio
DTSTAMP:20261121T005018Z
DTSTART;VALUE=DATE:20320830
DTEND;VALUE=DATE:20320831
SUMMARY:Velzatinib: Phase 3 readout est. (NCT07585266)
DESCRIPTION:Velzatinib\, phase 3\, Gastrointestinal Stromal Tumor.\nStudy: 
 A Study to Investigate Velzatinib Compared With Imatinib in Adult Particip
 ants With Previously Untreated Metastatic and/or Unresectable Gastrointest
 inal Stromal Tumors (StrateGIST Frontline)\nEstimated primary completion: 
 30 August 2032. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/velza
 tinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07585266
URL:https://assetmemo.bio/drug/velzatinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
